Alexza Pharmaceutica (ALXA) 1.0000 $ALXA
Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly Dividend
BusinessWire - Thu Aug 04, 3:05PM CDT
--Q2 2016 Financial Highlights
TPIC: 19.79 (-0.10), HTGC: 13.69 (+0.03), NUAN: 14.60 (+0.02), PFE: 34.68 (-0.12), BIND: 0.78 (-0.09), RLOC: 4.60 (unch), CPXX: 30.24 (unch), HTGY: 25.84 (unch), HTGZ: 25.59 (+0.09), GCI: 11.77 (-0.16), HTGX: 26.14 (+0.12), JAZZ: 123.31 (-0.52), ANAC: 99.06 (-0.14), EACQ: 9.73 (-0.15)
Alexza Pharmaceuticals Acquired by Ferrer
PR Newswire - Tue Jun 21, 7:00AM CDT
Alexza Pharmaceuticals, Inc. (OTC: ALXA, "Alexza"
and Grupo Ferrer Internacional, S.A. ("Ferrer" today announced the expiration of the tender offer (the "Offer" by Ferrer Pharma Inc., a wholly-owned indirect subsidiary of Ferrer ("Ferrer Pharma" , to purchase all of the outstanding shares of Alexza's common stock at a price (the "Offer Price" of $0.90 per share, net to the holder in cash (less any required withholding taxes and without interest), plus one contractual contingent value right (a "CVR" per share, which represents the right to receive a pro-rata share of up to four payment categories in an aggregate (i.e., to all CVR holders assuming all four payments are made) maximum amount of $32.8 million (after deduction of an estimated $2.2 million payment to Alexza's financial adviser for fees and expenses in connection with the transactions described herein and subject to further adjustment) if certain licensing payments and revenue milestones are achieved, net to the holder in cash (less any applicable withholding taxes and without interest).
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
BusinessWire - Mon May 16, 9:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or the "Company" (Nasdaq: ALXA) relating to the proposed buyout of the Company by Ferrer Pharma, Inc.
ALEXZA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Ferrer Pharma, Inc. May be Unfair to Shareholders
BusinessWire - Mon May 16, 12:01PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" (NASDAQ: ALXA) concerning the acquisition by Ferrer Pharma, Inc. Under the terms of the agreement, Alexza shareholders will only receive $0.90 per Alexza share owned and a contingent value right entitling the stockholder to receive a pro-rata share of up to four payment categories in an aggregate maximum amount of $35 million if specified milestones are achieved. The consideration is significantly lower than at least one analyst's estimated value of $1.25.
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Fri May 13, 10:15PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or the "Company" (Nasdaq: ALXA) relating to the proposed buyout of the Company by Ferrer Pharma, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Alexza Pharmaceuticals, Inc. to Ferrer Pharma, Inc. - ALXA
ACCESSWIRE - Fri May 13, 9:59AM CDT
NEW YORK, NY / ACCESSWIRE / May 13, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
Why is Alexza Pharmaceuticals (ALXA) Stock Soaring Today?
Madeleine Johnson - Zacks Investment Research - Tue May 10, 2:59PM CDT
On Tuesday, shares of pharmaceutical company Alexza Pharmaceuticals (ALXA) are soaring, up over 66% in afternoon trading after the company announced it has entered into a definitive agreement to be acquired by Spain-based Ferrer Pharma Inc.
Alexza to Cancel 2016 First Quarter Financial Results Earnings Call
PR Newswire - Tue May 10, 7:30AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company" today announced that it intends to issue a press release reporting financial results for the first quarter of fiscal 2016, as planned, immediately following the close of market on Wednesday, May 11, 2016. However, following the announcement on May 10, 2016, of Grupo Ferrer Internacional SA's proposed acquisition of Alexza, Alexza has elected not to conduct a conference call to discuss the quarterly financial results. The call was previously scheduled for May 11, 2016 at 5:00 p.m. Eastern Time.
Alexza to Report 2016 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 11, 2016
PR Newswire - Wed Apr 27, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company" will report results for its fiscal quarter ended March 31, 2016 on Wednesday, May 11, 2016, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time to provide a company update and discuss the financial results.
Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 10.76 (+0.02)
Alexza Reports Fourth Quarter and Year End 2015 Financial Results
PR Newswire - Mon Mar 28, 3:10PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company" today reported financial results for the quarter and year ended December 31, 2015. The net loss for the fourth quarter was $3.0 million compared to $6.7 million during the same quarter in 2014. The net loss for the years ended December 31, 2015 and 2014 was $21.3 million and $36.7 million, respectively. At December 31, 2015, Alexza had consolidated cash and cash equivalents of $7.8 million.
Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 237.76 (+3.22), AVXL: 3.03 (-0.03), ACOR: 24.34 (+0.26), BCLI: 2.43 (+0.04), FOLD: 6.69 (unch)
Global Insomnia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/65tkn8/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Insomnia Overview - Therapeutics Development - Pipeline Products for Insomnia - Overview - Pipeline Products for Insomnia - Comparative Analysis - Insomnia - Therapeutics under Development by Companies - Insomnia - Therapeutics under Investigation by Universities/Institutes - Insomnia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Insomnia - Products under Development by Companies - Insomnia - Products under Investigation by Universities/Institutes - Insomnia - Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evotec AG - Grupo Ferrer Internacional, S.A. - Heptares Therapeutics Limited - Intec Pharma ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Merck & Co., Inc. - Neurim Pharmaceuticals Ltd - Novartis AG - Reviva Pharmaceuticals Inc. - Rottapharm SpA - Shionogi & Co., Ltd. - Somnus Therapeutics, Inc. - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/65tkn8/insomnia
JNJ: 119.08 (-0.26), NTEC: 6.20 (+0.16), MRK: 62.90 (+0.11), ITCI: 40.63 (+0.29), NVS: 78.27 (-0.50)
New Strong Buy Stocks for December 31st
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
EARS: 1.71 (-0.14), ALLE: 71.84 (+0.62), AERI: 19.21 (-0.15), AVOL: 30.93 (-0.02)
New Strong Buy Stocks for December 29th
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AKAM: 55.07 (+0.17), ASNA: 7.80 (-0.34), AERI: 19.21 (-0.15), ARNA: 1.56 (+0.01)
Alexza Pharmaceuticals Announces Receipt of NASDAQ Staff Determination; Alexza to Request Hearing with NASDAQ Listing Qualifications Panel
PR Newswire - Tue Dec 22, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that on December 17, 2015, the Company received a letter from the Nasdaq Staff indicating that the Company had not regained compliance with the $35 million market capitalization requirement for continued listing on The Nasdaq Capital Market by the end of the previously granted compliance period, which expired on December 16, 2015. As a result, the Company would be subject to delisting unless it timely requests a hearing before a Nasdaq Listing Qualifications Panel (the "Panel" . Based on the foregoing, the Company intends to timely request a hearing before the Panel at which it will present its plan of compliance and request a further extension of time. The Panel has the discretion to grant the Company up to an additional 180 calendar days from December 17, 2015 to regain compliance. This request will automatically stay any delisting or suspension action pending the issuance of a final decision by the Panel and the expiration of any further extension granted by the Panel. There can be no assurance that the Panel will ultimately grant an extension of the compliance period.
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Tue Dec 22, 10:51AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch that have been attracting the attention of investors.
ARGS: 4.95 (unch), PSDV: 3.77 (-0.10), SRNE: 6.76 (+0.10)
Alexza Pharmaceuticals Announces Interim Results from its Phase 2a Study of AZ-002 (Staccato® alprazolam) in Epilepsy Patients
PR Newswire - Mon Dec 21, 3:10PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced interim results of its Phase 2a study of AZ-002 (Staccato® alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study. AZ-002 is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.
Epilepsy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfmq9k/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - Alexza Pharmaceuticals, Inc. - Allergan Plc - Anavex Life Sciences Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Biscayne Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - Epirus Biopharmaceuticals, Inc. - Glialogix, Inc. - GW Pharmaceuticals Plc - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - INSYS Therapeutics, Inc. - Iproteos S.L. - Others (30) For more information visit http://www.researchandmarkets.com/research/rfmq9k/epilepsy
AGN: 237.76 (+3.22), INSY: 14.36 (+0.09), CPRX: 0.96 (-0.05), AVXL: 3.03 (-0.03), ACOR: 24.34 (+0.26), CNCE: 9.71 (-0.01)
Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly Dividend
BusinessWire - Thu Aug 04, 3:05PM CDT
--Q2 2016 Financial Highlights
TPIC: 19.79 (-0.10), HTGC: 13.69 (+0.03), NUAN: 14.60 (+0.02), PFE: 34.68 (-0.12), BIND: 0.78 (-0.09), RLOC: 4.60 (unch), CPXX: 30.24 (unch), HTGY: 25.84 (unch), HTGZ: 25.59 (+0.09), GCI: 11.77 (-0.16), HTGX: 26.14 (+0.12), JAZZ: 123.31 (-0.52), ANAC: 99.06 (-0.14), EACQ: 9.73 (-0.15)
Alexza Pharmaceuticals Acquired by Ferrer
PR Newswire - Tue Jun 21, 7:00AM CDT
Alexza Pharmaceuticals, Inc. (OTC: ALXA, "Alexza"
and Grupo Ferrer Internacional, S.A. ("Ferrer" today announced the expiration of the tender offer (the "Offer" by Ferrer Pharma Inc., a wholly-owned indirect subsidiary of Ferrer ("Ferrer Pharma" , to purchase all of the outstanding shares of Alexza's common stock at a price (the "Offer Price" of $0.90 per share, net to the holder in cash (less any required withholding taxes and without interest), plus one contractual contingent value right (a "CVR" per share, which represents the right to receive a pro-rata share of up to four payment categories in an aggregate (i.e., to all CVR holders assuming all four payments are made) maximum amount of $32.8 million (after deduction of an estimated $2.2 million payment to Alexza's financial adviser for fees and expenses in connection with the transactions described herein and subject to further adjustment) if certain licensing payments and revenue milestones are achieved, net to the holder in cash (less any applicable withholding taxes and without interest). INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
BusinessWire - Mon May 16, 9:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or the "Company"
(Nasdaq: ALXA) relating to the proposed buyout of the Company by Ferrer Pharma, Inc. ALEXZA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Ferrer Pharma, Inc. May be Unfair to Shareholders
BusinessWire - Mon May 16, 12:01PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza"
(NASDAQ: ALXA) concerning the acquisition by Ferrer Pharma, Inc. Under the terms of the agreement, Alexza shareholders will only receive $0.90 per Alexza share owned and a contingent value right entitling the stockholder to receive a pro-rata share of up to four payment categories in an aggregate maximum amount of $35 million if specified milestones are achieved. The consideration is significantly lower than at least one analyst's estimated value of $1.25. SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Fri May 13, 10:15PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or the "Company"
(Nasdaq: ALXA) relating to the proposed buyout of the Company by Ferrer Pharma, Inc. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Alexza Pharmaceuticals, Inc. to Ferrer Pharma, Inc. - ALXA
ACCESSWIRE - Fri May 13, 9:59AM CDT
NEW YORK, NY / ACCESSWIRE / May 13, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
Why is Alexza Pharmaceuticals (ALXA) Stock Soaring Today?
Madeleine Johnson - Zacks Investment Research - Tue May 10, 2:59PM CDT
On Tuesday, shares of pharmaceutical company Alexza Pharmaceuticals (ALXA) are soaring, up over 66% in afternoon trading after the company announced it has entered into a definitive agreement to be acquired by Spain-based Ferrer Pharma Inc.
Alexza to Cancel 2016 First Quarter Financial Results Earnings Call
PR Newswire - Tue May 10, 7:30AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company"
today announced that it intends to issue a press release reporting financial results for the first quarter of fiscal 2016, as planned, immediately following the close of market on Wednesday, May 11, 2016. However, following the announcement on May 10, 2016, of Grupo Ferrer Internacional SA's proposed acquisition of Alexza, Alexza has elected not to conduct a conference call to discuss the quarterly financial results. The call was previously scheduled for May 11, 2016 at 5:00 p.m. Eastern Time. Alexza to Report 2016 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 11, 2016
PR Newswire - Wed Apr 27, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company"
will report results for its fiscal quarter ended March 31, 2016 on Wednesday, May 11, 2016, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time to provide a company update and discuss the financial results. Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 10.76 (+0.02)
Alexza Reports Fourth Quarter and Year End 2015 Financial Results
PR Newswire - Mon Mar 28, 3:10PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or the "Company"
today reported financial results for the quarter and year ended December 31, 2015. The net loss for the fourth quarter was $3.0 million compared to $6.7 million during the same quarter in 2014. The net loss for the years ended December 31, 2015 and 2014 was $21.3 million and $36.7 million, respectively. At December 31, 2015, Alexza had consolidated cash and cash equivalents of $7.8 million. Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles
M2 - Tue Feb 09, 6:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Parkinson's Disease Overview - Therapeutics Development - Pipeline Products for Parkinson's Disease - Overview - Pipeline Products for Parkinson's Disease - Comparative Analysis - Parkinson's Disease - Therapeutics under Development by Companies - Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes - Parkinson's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Parkinson's Disease - Products under Development by Companies - Parkinson's Disease - Products under Investigation by Universities/Institutes - Parkinson's Disease - Companies Involved in Therapeutics Development - Sample List of the 150 Companies Featured - AC Immune SA - Acelot, Inc. - Acorda Therapeutics, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - AFFiRiS AG - Alexza Pharmaceuticals, Inc. - Allergan Plc - Amabiotics SAS - Amarantus Bioscience Holdings, Inc. - American Gene Technologies International Inc. - Amicus Therapeutics, Inc. - Anavex Life Sciences Corp. - Angita B.V. - Antoxis Limited - APeT Holding BV - Aposense Ltd. - Araclon Biotech, S.L. - ArmaGen,Inc. - Arrien Pharmaceuticals, LLC - Bial - Portela & Ca, S.A. - Bio-Modeling Systems SAS - BioArctic Neuroscience AB - Biogen, Inc. - Bionature E.A. Ltd. - Biopharm GmbH - Biotie Therapies Corp. - BrainStorm Cell Therapeutics Inc. - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/6b8nmd/parkinsons
AGN: 237.76 (+3.22), AVXL: 3.03 (-0.03), ACOR: 24.34 (+0.26), BCLI: 2.43 (+0.04), FOLD: 6.69 (unch)
Global Insomnia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/65tkn8/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Insomnia Overview - Therapeutics Development - Pipeline Products for Insomnia - Overview - Pipeline Products for Insomnia - Comparative Analysis - Insomnia - Therapeutics under Development by Companies - Insomnia - Therapeutics under Investigation by Universities/Institutes - Insomnia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Insomnia - Products under Development by Companies - Insomnia - Products under Investigation by Universities/Institutes - Insomnia - Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evotec AG - Grupo Ferrer Internacional, S.A. - Heptares Therapeutics Limited - Intec Pharma ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Merck & Co., Inc. - Neurim Pharmaceuticals Ltd - Novartis AG - Reviva Pharmaceuticals Inc. - Rottapharm SpA - Shionogi & Co., Ltd. - Somnus Therapeutics, Inc. - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/65tkn8/insomnia
JNJ: 119.08 (-0.26), NTEC: 6.20 (+0.16), MRK: 62.90 (+0.11), ITCI: 40.63 (+0.29), NVS: 78.27 (-0.50)
New Strong Buy Stocks for December 31st
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
EARS: 1.71 (-0.14), ALLE: 71.84 (+0.62), AERI: 19.21 (-0.15), AVOL: 30.93 (-0.02)
New Strong Buy Stocks for December 29th
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AKAM: 55.07 (+0.17), ASNA: 7.80 (-0.34), AERI: 19.21 (-0.15), ARNA: 1.56 (+0.01)
Alexza Pharmaceuticals Announces Receipt of NASDAQ Staff Determination; Alexza to Request Hearing with NASDAQ Listing Qualifications Panel
PR Newswire - Tue Dec 22, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that on December 17, 2015, the Company received a letter from the Nasdaq Staff indicating that the Company had not regained compliance with the $35 million market capitalization requirement for continued listing on The Nasdaq Capital Market by the end of the previously granted compliance period, which expired on December 16, 2015. As a result, the Company would be subject to delisting unless it timely requests a hearing before a Nasdaq Listing Qualifications Panel (the "Panel"
. Based on the foregoing, the Company intends to timely request a hearing before the Panel at which it will present its plan of compliance and request a further extension of time. The Panel has the discretion to grant the Company up to an additional 180 calendar days from December 17, 2015 to regain compliance. This request will automatically stay any delisting or suspension action pending the issuance of a final decision by the Panel and the expiration of any further extension granted by the Panel. There can be no assurance that the Panel will ultimately grant an extension of the compliance period. 4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Tue Dec 22, 10:51AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch that have been attracting the attention of investors.
ARGS: 4.95 (unch), PSDV: 3.77 (-0.10), SRNE: 6.76 (+0.10)
Alexza Pharmaceuticals Announces Interim Results from its Phase 2a Study of AZ-002 (Staccato® alprazolam) in Epilepsy Patients
PR Newswire - Mon Dec 21, 3:10PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced interim results of its Phase 2a study of AZ-002 (Staccato® alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study. AZ-002 is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.
Epilepsy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfmq9k/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - Alexza Pharmaceuticals, Inc. - Allergan Plc - Anavex Life Sciences Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Biscayne Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - Epirus Biopharmaceuticals, Inc. - Glialogix, Inc. - GW Pharmaceuticals Plc - H. Lundbeck A/S - Hyundai Pharmaceutical Co., Ltd. - INSYS Therapeutics, Inc. - Iproteos S.L. - Others (30) For more information visit http://www.researchandmarkets.com/research/rfmq9k/epilepsy
AGN: 237.76 (+3.22), INSY: 14.36 (+0.09), CPRX: 0.96 (-0.05), AVXL: 3.03 (-0.03), ACOR: 24.34 (+0.26), CNCE: 9.71 (-0.01)
